The Enteric Flora in Intestinal Failure: Small Intestinal Bacterial Overgrowth and Gut-Derived Sepsis

Intestinal Failure: Diagnosis, Management and Transplantation

Volumn , Issue , 2009, Pages 167-184

  Quigley, Eamonn M M ^a   Quera, Rodrigo ^b   Abu Shanab, Ahmed ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Enteric flora in intestinal failure; Non alcoholic fatty liver disease (NAFLD); Normal flora gut homeostasis key factor; Probiotics for SIBO related complications; SIBO and immune effects; SIBO and morphological and metabolic effects; SIBO predisposing condition(s) reversal or removal; Small intestinal bacterial overgrowth (SIBO)

Indexed keywords

EID: 70049112047     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781405195805.ch19     Document Type: Chapter

References (181)

1. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci USA 2003;100:10452-10459.
2. Simon GL, Gorbach SL. The human intestinal microflora. Dig Dis Sci 1986;31:147-162.
3. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998;42:2-7.
4. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-519.
5. Neish AS. The gut microflora and intestinal epithelial cells: a continuing dialogue. Microbes Infect 2002;4:309-317.
6. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
7. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 2002;16:915-931.
8. Weiner HL. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest 2000;106:935-937.
9. Sartor RB. Mucosal immunology and mechanisms of gastrointestinal inflammation. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 8th ed. Philadelphia: WB Saunders Co, 2006;27-66.
10. Björkstén B, Sepp E, Julge K, et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108:516-520.
11. Singh VV, Toskes PP. Small bowel overgrowth: Presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004;7:19-28.
12. Bauer TM, Steinbrückner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001;96:2962-2967.
13. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal overgrowth syndrome. Am J Gastroenterol 1999;94:1327-1331.
14. Riordan SM, McIver CJ, Wakefield D, et al. Small intestinal mucosal immunology and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol 2001;96:494-500.
15. Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology 1997;113:1767-1778.
16. Gregg CR, Toskes PP. Enteric bacterial flora and small bowel bacterial overgrowth syndrome. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. 7th ed. Philadelphia: WB Saunders Co, 2002;1783-1793.
17. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg 1998;228:188-193.
18. Husebye E, Skar V, Hoverstad T, et al. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology 1995;109:1078-1089.
19. Van Felius ID, Akkermans LM, Bosscha K, et al. Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis. Neurogastroenterol and Motil 2003;15:267-276.
20. Quigley EMM, Thompson JS. The intestinal motor response to resection. Gastroenterology 1993;105:791-798.
21. Schimpl G, Feierl G, Linni K, et al. Bacterial translocation in short-bowel syndrome in rats. Eur J Pediatr Surg 1999;9:224-227.
22. Asensio AB, Garcia-Urkia N, Aldazabal P, et al. Incidence of bacterial translocation in four different models of experimental short bowel syndrome. Cir Pediatr 2003;16:20-25.
23. Maestri L, Fava G, Fontana M, et al. Small bowel overgrowth: a frequent complication after abdominal surgery in newborns. Pediatr Med Chir 2002;24:374-376.
24. Quigley EMM, Phillips SF, Dent J. Distinctive patterns of interdigestive motility at the canine ileocolonic junction. Gastroenterology 1984;87:836-844.
25. Quigley EMM, Borody TJ, Phillips SF, et al. Motility of the terminal ileum and ileocecal sphincter in healthy man. Gastroenterology 1984;87:857-866.
26. Hoffmann JC, Zeitz M. Small bowel disease in the elderly: Diarrhoea and malabsorption. Best Pract Res Clin Gastroenterol 2002;16:17-36.
27. Mitsui T, Kagami H, Kinomoto H, Kondo T, Shimaoka K: Small bowel bacterial overgrowth and rice malabsorption in healthy and physically disabled older adults. 2003;16:119-122.
28. Mitsui T, Shimaoka K, Goto Y, et al. Small bowel bacterial overgrowth is not seen in healthy adults but is in disabled older adults. Hepatogastroenterology 2006;53:82-85.
29. Castiglione F, Del Vecchio Blanco G, Rispo A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn's disease. J Clin Gastroenterol 2000;31:63-66.
30. Madrid AM, Soto L, Defilippi C, et al. Gastrointestinal motor involvement in scleroderma and its clinical correlation. Gastroenterol Latinoam 2002;13: 381.
31. Justino SR, Goncalves Dias MC, Maculevicius J, et al. Fasting breath hydrogen concentration in short bowel syndrome patients with colon in continuity before and after antibiotic therapy. Nutrition 2004;20:187-191.
32. O'Boyle CJ, MacFie J, Mitchell CJ, et al. Microbiology of bacterial translocation in humans. Gut 1998;42:29-35.
33. Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Gastroenterology 1990;98:302-309.
34. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidencebased review of indications and pitfalls in interpretation. Am J Gastroenterol 2002;97:1113-1126.
35. Clinically relevant breath tests in gastroenterological diagnositics-recommendations of the German Society for Neurogastroenterology and Motility as well as the German Society for Digestive and Metabolic Diseases. Z Gastroenterol 2005;43:1071-1090.
36. Stotzer PO, Kilander AF: Comparison of the 1-gram 14C-D-xylose breath test and the 50 gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. Digestion 2000;61:165-171.
37. Elphick DA, Chew TS, Higham SE, et al. Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? Gerontology 2005;51:396-401.
38. Thomas PD, Forbes A, Green J, et al: Guidelines for the investigation of chronic diarrhoea. Gut 2003;52(suppl V):v1-v15.
39. Ghoshal UC, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome, and its relationship with oro-cecal transit time. Indian J Gastroenterol 2006;25:6-10.
40. Riordan SM, MacIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal overgrowth. Am J Gastroenterol 1996;9:1795-1803.
41. Levitt MD, Ingelfinger FJ. Hydrogen gas and methane production in man. Ann NY Acad Sci 1965;150:75-81.
42. Melcher EA, Levitt MD, Slavin JL. Methane production and bowel function parameters in healthy subjects on low-and high-fiber diets. Nutr Cancer 1991;16:85-92.
43. Strocchi A, Levitt MD. Factors affecting hydrogen production and consumption by human fecal flora. The critical roles of hydrogen tension and methanogenesis. J Clin Invest 1992;89:1304-1311.
44. Gregg CR. Enteric bacterial flora and bacterial overgrowth syndrome. Semin Gastrointest Dis 2002;13:200-209.
45. Wanitschke R, Ammon HV. Effects of dihydroxy bile acids and hydroxy fatty acids on the absorption of oleic acid in the human jejunum. J Clin Invest 1978;61:178-186.
46. Saltzman JR, Russell RM. Nutritional consequences of intestinal bacterial overgrowth. Comp Ther 1994;20: 523-530.
47. Riordan SM, McIver CJ, Thomas DH, et al. Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol 1997;32:556-563.
48. King CE, Toskes PP. Protein-losing enteropathy in the human and experimental rat blind loop syndrome. Gastroenterology 1981;80:504-509.
49. Varcoe R, Haliday D, Tavill AS. Utilization of urea nitrogen for albumin synthesis in the stagnant loop syndrome. Gut 1974;15:898-902.
50. Shah SM, Roberts PJ, Watson CJ, et al. Relapsing encephalopathy following small bowel transplantation. Transplant Proc 2003;35:1565-1566.
51. Gurevitch J, Sela B, Jonas A, et al. D-lactic acidosis: a treatable encephalopathy in pediatric patients. Acta Paediatr 1993;82:119-121.
52. Angelet P, Compte MT, Cid JL, et al. Recurrent episodes of acidosis with encephalophaty in a hemodialysis program patient with short bowel syndrome. Nefrologia 2002;22:196-198.
53. Soler Palacin P, Garzon Lorenzo P, Castilla Fernandez Y, et al. D-lactic acidosis in an 11-year-old patient with short bowel syndrome. An Pediatr (Barc) 2006;64:385-387.
54. Ghoshal UC, Ghoshal U, Ayyagari A, et al. Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocaecal transit time. J Gastroenterol Hepatol 2003;18:540-547.
55. Stotzer PO, Johansson C, Mellstrom D, et al. Bone mineral density in patients with small intestinal bacterial overgrowth. Hepatogastroenterol 2003;50:1415-1418.
56. Mitsui T, Shimaoka K, Takagi C, et al. Small bowel bacterial overgrowth may not affect bone mineral density in older people. Clin Nutr 2005;24:920-924.
57. Carbonnel F, Cosnes J, Chevret S, et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. JPEN 1996;20:275-280.
58. Riordan SM, McIver CJ, Wakefield D, et al. Mucosal cytokine production in small-intestinal bacterial overgrowth. Scand J Gastroenterol 1996;31:977-984.
59. Kett K, Baklien K, Bakken A, et al. Intestinal B-cell isotype response in relation to local bacterial load: evidence for immunoglobulin A subclass adaptation. Gastroenterology 1995;109:819-825.
60. Riordan, McIver CJ, Wakefield D, et al. Luminal immunity in small intestinal bacterial overgrowth and old age. Scand J Gastroenterol 1996;31:1103-1109.
61. Ghoshal UC, Ghoshal U, Misra A, Choudhuri G. Partially responsive coeliac disease resulting from small intestinal bacterial overgrowth and lactose intolerance. BMC Gastroenterology 2004;4:10.
62. Tursi A, Brandimarte G, Giorgetti GM. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. AmJ Gastroenterol 2003;98:839-843.
63. Riordan, McIver CJ, Wakefield D, et al. Luminal antigliadin antibodies in small intestinal bacterial overgrowth. Am J Gastroenterol 1997;92:1335-1338.
64. Riordan, McIver CJ, Wakefield D, et al. Local and systemic complement activity in small intestinal bacterial overgrowth. Dig Dis Sci 1997;42:1128-1136.
65. Riordan SM, McIver CJ, Wakefield D, et al. Serum immunoglobulin and soluble IL-2 receptor levels in small intestinal bacterial overgrowth with indigenous gut flora. Dig Dis Sci 1999;44:939-944.
66. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725-740.
67. Berg RD. Bacterial translocation from the gastrointestinal tract. Adv Exp Med Biol 1999;473:11-30.
68. Kane TD, Johnson SR, Alexander JW, et al. Detection of intestinal bacterial translocation using PCR. J Surg Res 1996;63:59-63.
69. Kazez A, Saglam M, Doyzmaz MZ, et al. Detection of bacterial translocation during intestinal distention in rats using the polymerase chain reaction. Pediatr Surg Int 2001;17:624-627.
70. Such J, Frances R, Munoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002;36:135-141.
71. Frances R, Munoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004;53:860-864.
72. Albillos A, de la Hera, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208-217.
73. Sánchez E, Casafont F, Guerra A, et al. Role of intestinal bacterial overgrowth and intestinal motility in bacterial translocation in experimental cirrhosis. Rev Esp Enferm Dig 2005;97: 805-814.
74. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-433.
75. Zhang S, Wang W, Ren W, et al. Effects of lactulose on intestinal endotoxin and bacterial translocation in cirrhotic rats. Chin Med J 2003;116:767-771.
76. Zhang SC, Wang W, Ren WY, et al. Effects of cisapride on intestinal bacterial and endotoxin translocation in cirrhotic rats. Zhonghua Ganzangbing Zazhi 2003;11:539-541.
77. Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000;31:43-48.
78. Almeida J, Galhenage S, Yu J, et al. Gut flora and bacterial translocation in chronic liver disease.World J Gastroenterol 2006;12:1493-1502.
79. O'Boyle C, MacFie J, Dave K, et al. Alterations in intestinal barrier function do not predispose to translocation of enteric bacteria in gastroenterological patients. Nutrition 1998;14:358-362.
80. O'Brien DP, Nelson LA, Kemp CJ, et al. Intestinal permeability and bacterial translocation are uncoupled after small bowel resection. J Pediatr Surg 2002;37:390-394.
81. Riordan SM, McIver CJ, Thomas DH, et al. Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol 1997;32:556-563.
82. Steffen EK, Berg RD, Deitch EA. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis 1988;157:1023-1028.
83. Alverdy JC, Laughlin RS, Licheng W. Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined. Crit CareMed 2003;31:598-607.
84. Alverdy J, Holbrook C, Rocha F, et al. Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host: evidence for in vivo virulence expression in Pseudomonas aeruginosa. Ann Surg 2000;232:480-489.
85. Ferri M, Gabriel S, Gavelli A, et al. Bacterial translocation during portal clamping for liver resection. A clinical study. Arch Surg 1997;132:162-165.
86. Kanwar S, Windsor AC, Welsh F, et al. Lack of correlation between failure of gut barrier function and septic complications after major upper gastrointestinal surgery. Ann Surg 2000;231:88-95.
87. Reimund JM, Arondel Y, Finck G, et al. Catheterrelated infection in patients on home parenteral nutrition: results of a prospective survey: Clin Nutr 2002;21:33-38.
88. Catton JA, Dobbins BM, Wood JM, et al. The routine microbial screening of central venous catheters in home parenteral nutrition patients. Clin Nutr 2004;23:171-175.
89. Salzedas-Netto AA, Silva RM, Martins JL, et al. Can bacterial translocation be a beneficial event? Transplant Proc 2006;38:1836-1837.
90. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
91. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-687.
92. Wigg AJ, Roberts-Thomson IC, et al. The role of small intestinal overgrowth, intestinal permeability, endotoxemia, and TNF alpha in the pathogenesis of nonalcoholic steatohepatitis. Gut 2001;48:206-211.
93. Aguirre V, Uchida T, Yenush L, et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem 2000;275: 9047-9054.
94. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-687.
95. Szabo G, Velayudham A, Romics L, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice (the role of toll-like receptors 2 and 4). Alcohol Clin Exp Res 2005;29:S140-S145.
96. Enotomo E, Ikejima K, Bradford BU, et al. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol 2000;15:D20-25.
97. Cope K, Ribsy T, Diehl AM. Increased gastrointestinal ethanol production in obese mice. Implications for fatty liver pathogenesis. Gastroenterology 2000;119:1340-1347.
98. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350.
99. Loguercio C, De Simone T, Federico A, et al. Gut-liver axis: a new point of attack to treat chronic liver damage. Am J Gastroenterol 2002;97:244-246.
100. Quigley EMM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993;104:286-301.
101. Seehofer D, Rayes N, Schiller R, et al. Probiotics partly reverse increased bacterial translocation after simultaneous liver resection and colonic anastomosis in rats. J Surg Res 2004;117:262-271.
102. Di Stefano M, Miceli E, Missanelli A, Corazza GR. Treatment of small intestine bacterial overgrowth. Eur Rev Med Pharmacol Sci 2005;9:217-222.
103. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124:1111-1134.
104. Thompson JS, Quigley EMM, Adrian TE. Effect of intestinal tapering and lengthening on intestinal structure and function. Am J Surg 1995;169:111-119.
105. Cicalese L, Sileri P, Green M, et al. Bacterial translocation in clinical intestinal transplantation. Transplantation 2001;71:1414-1417.
106. Di Lorenzo C, Reddy SN, Villanueva-Meyer J, et al. Cisapride in children with chronic intestinal pseudoobstruction. An acute, double-blind, crossover, placebocontrolled trial. Gastroenterology 1991;101:1564-1570.
107. Abell TL, Camilleri M, DiMango EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991;36:616-620.
108. Hyman PE, Di Lorenzo C, McAdams L, et al. Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastroenterol 1993;88:832-836.
109. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995;40:1892-1901.
110. Perlemuter G, Cacoub P, Chaussade S, et al. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum 1999;42:1545-1549.
111. Von der Ohe MR, Camilleri M, Thomforde GM, Klee GG. Differential regional effects of octreotide on human gastrointestinal motor function. Gut 1995;36:734-738.
112. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991;325:1461-1467.
113. Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A, et al. The effects of ABT-29 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 1999;29:33-40.
114. Zhang SC,WangW, RenWY, et al. Effect of cisapride on intestinal bacterial and endotoxin translocation. World J Gastroenterol 2003;9:543-548.
115. Pardo A, Bartoli R, Lorenzo-Zuñiga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000;31:858-863.
116. Wang XD, Soltestz V, Andersson R. Cisapride prevents enteric bacterial overgrowth and translocation by improvement of intestinal motility in rats with acute liver failure. Eur Surg Res 1996;28:402-412.
117. Kaufman SS, Losecke CA, Lupo JV, et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J Pediatr 1997;131:356-361.
118. Castiglione F, Rispo A, Di Girolama E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:1107-1112.
119. Di Steffano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000;14:551-556.
120. Kumar A, Forsmark CE, Toskes PP. The response of small bowel bacterial overgrowth to treatment: effects of coexisting conditions. Gastroenterology 1996;110:A340.
121. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006;52:89-95.
122. Kaye SA, Lim SG, Taylor M, et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol 1995;34:265-269.
123. Goldstein F, Mandle RJ, Schaedler RW. The blindloop syndrome and its variants. Microbiologic aspects of diagnosis and treatment. Am J Gastroenterol 1973;60:255-264.
124. Attar A, Flourié B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowthrelated chronic diarrhea: a crossover randomized trial. Gastroenterology 1999;117:794-797.
125. Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998;27:155-160.
126. Kubota A, Okada A, Imura K, et al. The effect of metronidazole on TPN-associated liver dysfunction in neonates. J Pediatr Surg 1990;25:618-621.
127. Halperin ML, Kamel KS. D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Kidney Int 1996;49:1-8.
128. Bongaerts GP, Tolboom JJ, Naber AH, et al. Role of bacteria in the pathogenesis of short bowel syndrome-associated D-lactic academia. Microb Pathog 1997;22:285-293.
129. Jimenez Almonacid P, Calleja Kempin J, Vasquez Estevez J, et al. Bacterial translocation in intestinal transplant. Cir Pediatr 1999;12:56-60.
130. BiffiR, Privitera G, Matinato C, et al. Parenteral antibiotics and selective decontamination do not prevent enteric bacterial overgrowth or translocation observed in a swine model of small bowel transplantation. J Surg Res 1995;58:391-394.
131. Daxboeck F, Rabitsch W, Blacky A, et al. Influence of selective bowel decontamination on the organisms recovered during bacteremia in neutropenic patients. Infect Control Hosp Epidemiol 2004;25:685-689.
132. Bouter H, Schippers EF, Luelmo SA, et al. No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: a randomized, placebo-controlled trial. Crit Care Med 2002;30:38-43.
133. Lingnau W, Berger J, Javorsky F, et al. Changing bacterial ecology during a five-year period of selective intestinal decontamination. J Hosp Infect 1998;39:195-206.
134. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001;34:32-37.
135. Rolando N, Wade JJ, Stangou A, et al. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. Liver Transpl Surg 1996;2:8-13.
136. Luiten EJ, Hop WC, Endtz HP, Bruining HA. Prognostic importance of gram-negative intestinal colonization preceding pancreatic infection in severe acute pancreatitis. Results of a controlled clinical trial of selective decontamination. Intensive Care Med 1998;24:438-445.
137. Dervenis C, Smailis D, Hatzitheoklitos E. Bacterial translocation and its prevention in acute pancreatitis. J Hepatobiliary Pancreat Surg 2003;10:415-418.
138. Kuo PC, Bartlett ST, Lim JW, et al. Selective bowel decontamination in hospitalized patients awaiting liver transplantation. Am J Surg 1997;174:745-748.
139. Tetteroo GW,Wagenvoort JH, Bruining HA. Bacteriology of selective decontamination: efficacy and rebound colonization. J Antimicrob Chemother 1994;34:139-148.
140. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401-1412.
141. Roberfroid MB. Prebiotics: preferential substrates for specific germs? Am J Clin Nutr 2001;73: 406S-9.
142. Bouhnik Y, Flourie B, D'Agay-Abensour L, et al. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr 1997;127:444-448.
143. Duggan C, Gannon J,WalkerWA. Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr 2002;75:789-808.
144. Gnoth MJ, Kunz C, Kinne-Saffran E, Rudloff S. Human milk oligosaccharides are minimally digested in vitro. J Nutr 2000;130:3014-3020.
145. Dai D, Walker WA. Protective nutrients and bacterial colonization in the immature human gut. Adv Pediatr 1999;46:353-382.
146. Liu Q, Duan ZP, Ha da K, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-1449.
147. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation-a randomized, double-blind trial. Am J Transplant 2005;5:125-130.
148. Kanazawa H, Nagino M, Kamiya S, et al. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg 2005;390:104-113.
149. Bauer TM, Fernandez J, Navasa M, et al. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 2002;36:501-506.
150. Diplock AT, Aggett PJ, Ashwell M, et al. Scientific concepts of functional foods in Europe: consensus document. Br J Nutr 1999;81:s1-27.
151. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics-a comparison of functionality and efficacy. Int J Food Microbiol 2004;96:219-233.
152. Murphy LM, Byrne FR, Collins K, et al. Evaluation and characterisation of probiotic therapy in the CD45RBHI transfer model of colitis. Gastroenterology 1999;116:A780.
153. Shanahan F. Probiotics: a perspective on problems and pitfalls. Scand J Gastroenterol 2003;38(suppl): 34-36.
154. Castagliuolo I, Riegler MF, Valenik L, La Mont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999;67:302-307.
155. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-591.
156. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988-997.
157. Akhtar M, Watson JL, Nazli A, McKay DM. Bacterial DNA evokes epithelial IL-8 production by a MAPKdependent, NF-Kappa β-independent pathway. FASEB J 2003;17:1319-1321.
158. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-980.
159. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528.
160. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-1373.
161. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286:G613-G626.
162. Heyman M,Ménard S. Probiotic microorganisms: how they affect intestinal pathophysiology. Cell Mol Life Sci 2002;59:1151-1165.
163. Ménard S, Heyman M. Modulation of epithelial cell function and local immune system by probiotics: mechanisms involved. In: Goktepe I, Juneja VK, Ahmedna M, eds. Probiotics in Food Safety and Human Health. Boca Raton, Florida: Taylor and Francis, 2006.
164. Eizaguirre I, Urkia NG, Asencio AB, et al. Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome. J Pediatr Surg 2002;37:669-702.
165. Garcia-Urkia N, Asensio AB, Zubillaga Aspiroz I, et al. Beneficial effects of bifidobacterium lactis in the prevention of bacterial translocation in experimental short bowel syndrome. Cir Pediatr 2002;15:162-165.
166. Li Y, Shimizu T, Hosaka A, et al. Effects of bifidobacterium breve supplementation on intestinal flora of low birth weight infants. Pediatr Int 2004;46:509-515.
167. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005;115:1-4.
168. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005;147: 192-196.
169. Young RJ, Vanderhoof JA. Probiotic therapy in children with short bowel syndrome and bacterial overgrowth. Gastroenterology 1997;112:A916.
170. Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. acidophilus strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires) 2002;62:159-163.
171. Stotzer PO, Blomberg L, Conway Pl, Henriksson A, Abrahamsson H. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD. Scand J Infect Dis 1996;28:615-619.
172. Uchida H, Yamamoto H, Kisadi Y, et al. D-lactic acidosis in short bowel syndrome managed with antibiotics and probiotics. J Pediatr Surg 2004;39:634-636.
173. Tsunoda A, Shibusawa M, Tsunoda Y, et al. Effect of Lactobacillus casei on a novel murine model of abdominal sepsis. J Surg Res 2002;107:37-43.
174. Gan BS, Kim J, Reid G, Cadieux P, Howard JC. Lactobacillus fermentum RC-14 inhibits Staphlococcus aureus infection of surgical implants in rats. J Infect Dis 2002;185:1369-1372.
175. Seehofer D, Rayes N, Schiller R, et al. Probiotics partly reverse increased bacterial translocation after simultaneous liver resection and colonic anastomosis in rats. J Surg Research 2004;117:262-271.
176. Rayes N, Seehofer D, Muller AR, et al. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery-results of a prospective trial. Z Gastroenterol 2002;40:869-876.
177. McNaught CE, Woodcock NP, MacFie J, Mitchell CJ. A prospective randomized study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut 2002;51:827-831.
178. Anderson AD, McNaught CE, Jain PK, MacFie J. Randomised clinical trial of symbiotic therapy in elective surgical patients. Gut 2004;53:241-245.
179. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725-740.
180. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775-780.
181. Mäkeläinen H, Tahvonen R, Salminen S, Ouwehand AC. In vivo safety assessment of two Bifidobacterium longus strains. Microbiol Immunol 2003;47:911-914.